Galectin Therapeutics Inc (GALT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $307.59M
Last updated: Nov 17, 2026 at 11:02 AM ET
Galectin Therapeutics Inc (GALT) Competitors
The companies most similar to Galectin Therapeutics are Greenwich Lifesciences (GLSI), Tectonic Therapeutic (TECX) and Larimar Therapeutics (LRMR). By market cap, Galectin Therapeutics ranks 6th of the 13 companies on this page; Shattuck Labs (STTK) is the largest at $473.57M.
Peer Comparison
GALT's ROIC of 671.1% is above the peer median of -6.7%, and its revenue growth of 0.0% is in line with the median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Galectin Therapeutics (GALT) | $307.59M | N/A | N/A | 0.0% | 671.1% | 0.0% | 0.00% |
| Greenwich Lifesciences Inc (GLSI) | $219.29M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Tectonic Therapeutic, Inc. (TECX) | $413.27M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Larimar Therapeutics Inc (LRMR) | $313.73M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Alector Inc (ALEC) | $378.15M | 7.3x | 1.7x | 23.9% | N/A | 4896.0% | 0.00% |
| Fulcrum Therapeutics Inc (FULC) | $287.96M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Cartesian Therapeutics Inc. (RNAC) | $193.69M | N/A | 179.8x | 0.0% | 147.2% | -92.9% | 0.00% |
| Lineage Cell Therapeutics Inc (LCTX) | $231.35M | N/A | 18.7x | 16.2% | -6.7% | -61.0% | 0.00% |
| Gyre Therapeutics Inc. (GYRE) | $471.74M | N/A | 3.8x | -22.7% | N/A | 0.7% | 0.00% |
| Nautilus Biotechnology Inc (NAUT) | $295.50M | N/A | 630.2x | 0.0% | N/A | 0.0% | 0.00% |
| Protalix Biotherapeutics Inc (PLX) | $257.17M | 12.1x | 2.9x | 24.3% | N/A | 22.8% | 0.00% |
| Shattuck Labs Inc (STTK) | $473.57M | N/A | N/A | 0.0% | N/A | -66.6% | 0.00% |
| Cellectis SA (CLLS) | $118.86M | N/A | 1.8x | 0.0% | -74.1% | -85.4% | 0.00% |
| Peer median | $291.73M | 9.7x | 3.8x | 0.0% | -6.7% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Galectin Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Greenwich Lifesciences Inc (GLSI) | Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for breast and other HER2 /... | GLSI competitors |
| Tectonic Therapeutic, Inc. (TECX) | Tectonic Therapeutic, Inc. engages in the discovery of antibodies and other biologic drugs targeting G-protein-coupled receptors (GPCRs) to develop novel... | TECX competitors |
| Larimar Therapeutics Inc (LRMR) | Larimar Therapeutics, Inc., a clinical-stage biotechnology company, is focused on developing treatments for rare diseases. | LRMR competitors |
| Alector Inc (ALEC) | Alector, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of neurodegenerative diseases. | ALEC competitors |
| Fulcrum Therapeutics Inc (FULC) | Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined... | FULC competitors |
| Cartesian Therapeutics Inc. (RNAC) | Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs... | RNAC competitors |
| Lineage Cell Therapeutics Inc (LCTX) | Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment... | LCTX competitors |
| Gyre Therapeutics Inc. (GYRE) | Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases. | GYRE competitors |
| Nautilus Biotechnology Inc (NAUT) | Nautilus Biotechnology, Inc., a development-stage life sciences company, is dedicated to creating platform technology to quantify and unlock proteome... | NAUT competitors |
| Protalix Biotherapeutics Inc (PLX) | Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its... | PLX competitors |
| Shattuck Labs Inc (STTK) | Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapies for the treatment of cancer and autoimmune diseases in the United States. | STTK competitors |
| Cellectis SA (CLLS) | Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors... | CLLS competitors |
Frequently Asked Questions About GALT
Who are Galectin Therapeutics' main competitors?
The companies most similar to Galectin Therapeutics include Greenwich Lifesciences (GLSI), Tectonic Therapeutic (TECX), Larimar Therapeutics (LRMR), Alector (ALEC) and Fulcrum Therapeutics (FULC), listed from the closest match.
Who is Galectin Therapeutics' biggest competitor?
Shattuck Labs (STTK) is the largest of the similar companies at $473.57M; Greenwich Lifesciences (GLSI) is the closest match by business profile, size, sector and industry.
How does GALT stock compare with its competitors?
GALT's net margin is 0.0% against a peer median of 0.0%.
Which of Galectin Therapeutics' competitors pays a higher dividend?
Galectin Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Galectin Therapeutics bigger than its competitors?
No. Galectin Therapeutics is 6th by market cap among the 13 companies on this page; the largest is Shattuck Labs (STTK) at $473.57M.
GALT pages: Overview, Earnings, Forecast, Financials, Competitors